Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: ZMAT1 acts as a tumor suppressor in pancreatic ductal adenocarcinoma by inducing SIRT3/p53 signaling pathway

Fig. 1

ZMAT1 is down-regulated and correlates with unfavorable clinical characteristics and adverse outcome in Pancreatic Ductal Adenocarcinoma (PDAC). A Down-regulation of ZMAT1 in PDAC was identified in GEPIA database. B Down-regulation of ZMAT1 was identified in PDAC in Oncomine database (Pei’s dataset and Ishikawa’s dataset). C Down-regulation of ZMAT1 was identified in PDAC in three individual GEO datasets (GSE62165, GSE62452 and GSE16515). D The mRNA low-expression levels of ZMAT1 were identified in PDAC tissues and normal pancreas tissues of 25 samples. E Representative images of ZMAT1 staining in PDAC specimens and normal pancreas tissues. F Immunohistochemistry staining showed the protein levels of ZMAT1 were down-regulated in PDAC tissues. G ZMAT1 expression of PDAC was significantly correlated with differentiation, TNM stage, CA19-9 index and lymph nodes metastasis. H Multivariate Cox regression analyses showed low expression of ZMAT1 was independent risk factor for overall survival (OS) and disease-free survival (DFS) of 122 PDAC patients from validation cohort. I-J Kaplan–Meier analyses showed PDAC patients with high expression of ZMAT1 had superior OS and DFS than those with low expression in both TCGA cohort (I) and validation cohort (J). T, tumor; N, normal; OS, overall survival; DFS, disease-free survival. CA19-9, carbohydrate antigen 19–9. All * P-value < 0.05, ** P-value < 0.01, *** P-value < 0.001. Scale bars: 200 μm. P-values were determined by Non-parametric Mann–Whitney U-test in A-C. P-values were assessed by two-tailed t-tests in D and F. P-values were determined by χ2 tests or Fisher’s exact tests in G. The Hazard Ratios (HR) and P-values by the log-rank (Mantel-Cox) test are calculated in H-J

Back to article page